Article
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
Antimicrobial agents and chemotherapy - 1 Apr 2016
Lockhart Shawn R, Fothergill Annette W, Iqbal Naureen, Bolden Carol B, Grossman Nina T, Garvey Edward P, Brand Stephen R, Hoekstra William J, Schotzinger Robert J, Ottinger Elizabeth, Patterson Thomas F, Wiederhold Nathan P
Abstract excerpt
Thein vitroactivities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel ofCryptococcus neoformansandCryptococcus gattiiisolates. VT-1129 demonstrated potent activities against bothCryptococcusspecies as demonstrated by low MIC50and MIC90values. ForC. gattii, thein vitropotency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.